ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2667

Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort

Manuel Ugarte-Gil1,2, Ines Segami3,4, Guillermina Harvey5, Guillermo J. Pons-Estel6, Rosana Quintana7, Cristina Reategui-Sokolova8, Jorge Cieza4, Luis J. Catoggio9, Mercedes Garcia10, Verónica Saurit11, Francisco Caeiro12, Cristina Drenkard13, Guillermo Berbotto14, Emilia Sato15, Lilian Costallat16, Eloisa Bonfa17, Joao C. Tavares Brenol18, Nilzio A Da Silva19, Fernando Cavalcanti20, Antonio Iglesias-Gamarra21, Marlene Guibert-Toledano22, Gil A. Reyes22, Loreto Massardo23, Oscar J Neira24, Mario H Cardiel25, Leonor Barile26, Mary Carmen Amigo27, Luis H. Silveira28, Ignacio Garcia de la Torre29, Eduardo Acevedo-Vasquez2, Rosa Chacón-Díaz30, Maria H Esteva Spinetti31, Graciela S. Alarcón32,33 and Bernardo A Pons-Estel7, 1Rheumatology, Universidad Científica del Sur, Lima, Peru, 2Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3Universidad Nacional Mayor de San Marcos, Lima, Peru, 4Hospital Edgardo Rebagliati Martins. EsSalud, Lima, Peru, 5Escuela de Estadística, Universidad Nacional de Rosario, Rosario, Argentina, 6Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, 7Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, 8Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 9Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 10Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, 11Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 12Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 13Medicine/Rheumatology, Emory University, Atlanta, GA, 14Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, 15Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 16Universidade Estadual da Campinas, Campinas, Brazil, 17Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 18Hospital da Clinicas da Porto Alegre, Porto Alegre, Brazil, 19Faculdade de Medicina da Universidade Federal de Goiás, Goiania, Brazil, 20Universidade Federal da Pernambuco, Pernambuco, Brazil, 21Universidad Nacional de Colombia, Bogota, Colombia, 22Centro de Investigaciones Médico-Quirúrgicas (CIMEQ), Havana, Cuba, 23Centro de Biología Celular y Biomedicina (CEBICEM), Universidad San Sebastián, Santiago, Chile, 24Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile, 25Centro de Investigación Clínica de Morelia, Morelia, Mexico, 26Hospital Ángeles del Pedregal, Mexico, Mexico, 27Rheumatology, Centro Medico ABC, Mexico, Mexico, 28Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, 29Hospital General de Occidente, Guadalajara, Mexico, 30Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, 31Hospital Central de San Cristóbal, San Cristobal, Venezuela (Bolivarian Republic of), 32Universidad Peruana Cayetano Heredia, Lima, Peru, 33Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Activity score, outcomes and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Disease activity is one of the major predictors of damage accrual and mortality in systemic lupus erythematosus (SLE). Glucocorticoid use, especially in high dose, could underestimate the inflammatory status in SLE patients. Based on that, a modification of the SLEDAI accounting for glucocorticoid dose has been proposed, the SLEDAI glucocorticoid index (SGI)1. The aim of this study is to evaluate the impact of SGI and Mex-SLEDAI GI (M-SGI) as predictors of damage and mortality.

 

Methods: Patients from a multinational, multiethnic Latin American cohort were included in these analyses. SGI was calculated based on the impact of glucocorticoids proposed by the Toronto Cohort1. The same value for the impact of glucocorticoid was used for developing an M-SGI. Damage accrual was evaluated using the SLICC/ACR damage index (SDI). To evaluate the impact of SGI and M-SGI on the first increase on damage and on mortality, Cox regression models were performed, adjusting for gender, age at diagnosis, ethnicity, medical coverage, place of residence, educational level, SDI at baseline and antimalarial, glucocorticoid and immunosuppressive drugs use before baseline. Similar models were applied for the SLEDAI and the Mex-SLEDAI. All confounders were evaluated at or before baseline, and disease activity indices were evaluated as a time-dependent variable.

 

Results: One thousand three-hundred and twenty-one patients were included, median (25th-75th) age at diagnosis was 27.0 (20.0-37.0) years, 582 (44.1%) were Mestizo, 532 (40.3%) Caucasian, and 207 (15.7%) other. Median SLEDAI was 4 (0-12), Mex-SLEDAI was 3 (0-6), SGI was 7 (4-12) and M-SGI was 5 (2-9). Median follow-up was 4.3 (2.1-5.9) years. During follow up, sixty-nine patients (5.2%) died and 323 (24.5%) accrued new damage. The median values for the disease activity indices as a function of damage and mortality are depicted in Table 1. The corresponding hazard ratios are depicted in Table 2.

 

Conclusion: SGI and M-SGI predicted new damage and mortality in SLE patients independently of other well-known risk factors. However, their impact seems to be similar to those of the original versions of these instruments.

References

1. Touma Z, Gladman D, Su J, Urowitz M. 11 Development and initial validation of a novel lupus disease activity index to account for glucocorticoids: SLEDAI-2K glucocorticoids index (SGI). Lupus Sci Med 2017;4 :doi: 10.1136/lupus-2017-000215.11

 


Disclosure: M. Ugarte-Gil, None; I. Segami, None; G. Harvey, None; G. J. Pons-Estel, None; R. Quintana, None; C. Reategui-Sokolova, None; J. Cieza, None; L. J. Catoggio, None; M. Garcia, None; V. Saurit, None; F. Caeiro, None; C. Drenkard, ILAR, 2,PANLAR, 2; G. Berbotto, None; E. Sato, None; L. Costallat, None; E. Bonfa, Fundação de Amparo à Pesquisa do Estado de São Paulo, 2,Conselho Nacional de Desenvolvimento Científico e Tecnológico, 2; J. C. Tavares Brenol, None; N. A. Da Silva, None; F. Cavalcanti, None; A. Iglesias-Gamarra, None; M. Guibert-Toledano, None; G. A. Reyes, None; L. Massardo, None; O. J. Neira, None; M. H. Cardiel, Gilead, Pfizer Inc, Roche, 2,Eli Lilly, Pfizer Inc, 5,Eli Lilly, Pfizer Inc, 8; L. Barile, None; M. C. Amigo, None; L. H. Silveira, None; I. Garcia de la Torre, None; E. Acevedo-Vasquez, None; R. Chacón-Díaz, None; M. H. Esteva Spinetti, None; G. S. Alarcón, None; B. A. Pons-Estel, None.

To cite this abstract in AMA style:

Ugarte-Gil M, Segami I, Harvey G, Pons-Estel GJ, Quintana R, Reategui-Sokolova C, Cieza J, Catoggio LJ, Garcia M, Saurit V, Caeiro F, Drenkard C, Berbotto G, Sato E, Costallat L, Bonfa E, Tavares Brenol JC, Da Silva NA, Cavalcanti F, Iglesias-Gamarra A, Guibert-Toledano M, Reyes GA, Massardo L, Neira OJ, Cardiel MH, Barile L, Amigo MC, Silveira LH, Garcia de la Torre I, Acevedo-Vasquez E, Chacón-Díaz R, Esteva Spinetti MH, Alarcón GS, Pons-Estel BA. Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/sledai-and-mex-sledai-glucocorticoid-indices-as-predictors-of-damage-and-mortality-in-multinational-multiethnic-latin-american-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sledai-and-mex-sledai-glucocorticoid-indices-as-predictors-of-damage-and-mortality-in-multinational-multiethnic-latin-american-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology